Verastem Inc. (VSTM) carries a Roarable Rating of E (Strong Sell) with 24/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Verastem Inc. (VSTM) slipped -1.78% to $9.66, trading at 84% of its 52-week range ($3.43 – $10.82). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Verastem has given shareholders a rough ride over the longer term, yet the share price has moved sharply enough at times to keep the story alive. With that backdrop, the live question is whether today's valuation can be
BAAR, Switzerland, October 28, 2026--Novocure (Nasdaq: NVCR) announced today that it has entered into a clinical trial collaboration and supply agreement with Verastem Oncology to evaluate the use of Novocure’s Tumor Tre
Kiniksa Pharmaceuticals International, plc (KNSA) delivered earnings and revenue surprises of +75.00% and +10.19%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the
Verastem Oncology reported initial multi tumor data from its TARGET D 101 Phase 1/2 trial, showing robust clinical activity and a favorable safety and tolerability profile for VS-7375 across KRAS G12D-mutated pancreatic,
BOSTON, October 22, 2026--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a
Incyte Corporation shares ESMO 2026 highlights: KRAS G12D, INCA33890 and CDK2 combos show solid tumor promise ahead of Jakafi LOEâclick for more on INCY stock.
BTIG analyst Jeet Mukherjee reiterates Verastem (NASDAQ:VSTM) with a Buy and maintains $24 price target.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on VSTM today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for VSTM. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Verastem Inc. (VSTM) ranks #994 by composite RQD confidence (24/100, grade E) and #340 by equity capitalization ($1.17B). Within this direct 5-issuer industry benchmark cohort, AMPH leads on earnings valuation at 11.7x trailing P/E, while AMPH leads on capital efficiency and profitability with 9.0% ROIC and 49.5% gross margin. AMPH currently holds the highest overall quantitative score in the immediate peer group at 71/100 (B-) compared with VSTM at 24/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| VSTM
ACTIVE
Verastem Inc. | E | 24/100 | — | — | -35.0% | -1.78% | $1.17B | Benchmark Subject |
| RAPP Rapport Therapeutics Inc. | D- | 43/100 | — | — | -22.9% | +7.60% | $1.16B | /rapp-vs-vstm → |
| AMPH Amphastar Pharmaceuticals Inc. | B- | 71/100 | 11.7x | 49.5% | 9.0% | +2.28% | $1.15B | /amph-vs-vstm → |
| AVLN Avalyn Pharma Inc. | D | 49/100 | — | — | — | -0.12% | $1.14B | /avln-vs-vstm → |
| SPTX Seaport Therapeutics Inc. | D+ | 56/100 | — | — | — | +3.53% | $1.13B | /sptx-vs-vstm → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Verastem Inc. (VSTM) reported GAAP revenue of $30.9M (+209.1% vs. FY2024 revenue of $10.0M ) , GAAP net income of -$209.5M, operating cash flow of -$137.5M, and free cash flow of -$137.5M (-31.2% YoY). On the balance sheet, VSTM closed FY2025 with $246.4M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $30.9M | -$209.5M | -$137.5M | -$137.5M | $246.4M | — |
| FY2024 (FY) | 2024-12-31 | $10.0M | -$130.6M | -$104.8M | -$104.8M | $101.5M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$87.4M | -$86.5M | -$86.5M | — | — |
As of 2026-11-01, Verastem Inc. (NASDAQ: VSTM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 24/100 at a spot price of $9.66 (-1.78% 1D, market cap $1.17B). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, VSTM ranks #994 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VSTM carries a Roarable E (24/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, RAPP (Rapport Therapeutics Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -22.9%, cap $1.16B) and AMPH (Amphastar Pharmaceuticals Inc.) posts a B- grade (71/100 RQD, P/E 11.7x, ROIC 9.0%, cap $1.15B). Among the 5-stock peer group, AMPH leads on earnings multiple (11.7x) while AMPH leads on capital efficiency (9.0% ROIC).
Per VSTM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001526119), Verastem Inc. generated $30.9M in revenue (+209.1% YoY), -$209.5M in net income, and -$137.5M in free cash flow against $246.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
VSTM last traded at $9.66 (-1.78% on volume of 1,939,781 shares), positioning the stock +18.38% above its 50-day simple moving average ($8.16) and +56.56% above its 200-day simple moving average ($6.17). Across its 52-week range of $3.43 to $10.82, VSTM sits at the 84.3% percentile with a 14-day RSI of 61.7 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($8.45 to $10.87).
Why VSTM Stock slipped -1.78% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.